Does the media prefer RZLT or COYA?

In the previous week, Rezolute had 2 more articles in the media than Coya Therapeutics. MarketBeat recorded 4 mentions for Rezolute and 2 mentions for Coya Therapeutics. Coya Therapeutics' average media sentiment score of 0.72 beat Rezolute's score of 0.31 indicating that Coya Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Rezolute 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Coya Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer CABA or COYA?

In the previous week, Cabaletta Bio and Cabaletta Bio both had 2 articles in the media. Cabaletta Bio's average media sentiment score of 0.95 beat Coya Therapeutics' score of 0.72 indicating that Cabaletta Bio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cabaletta Bio 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Coya Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is COYA or PRTA more profitable?

Prothena has a net margin of -260.92% compared to Coya Therapeutics' net margin of -266.10%. Prothena's return on equity of -43.44% beat Coya Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Coya Therapeutics -266.10% -55.86% -48.86% Prothena -260.92% -43.44% -36.87%

Does the media favor COYA or PRTA?

In the previous week, Coya Therapeutics had 1 more articles in the media than Prothena. MarketBeat recorded 2 mentions for Coya Therapeutics and 1 mentions for Prothena. Prothena's average media sentiment score of 1.25 beat Coya Therapeutics' score of 0.72 indicating that Prothena is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Coya Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Prothena 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer COYA or RGNX?

In the previous week, REGENXBIO had 4 more articles in the media than Coya Therapeutics. MarketBeat recorded 6 mentions for REGENXBIO and 2 mentions for Coya Therapeutics. Coya Therapeutics' average media sentiment score of 0.72 beat REGENXBIO's score of -0.18 indicating that Coya Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Coya Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive REGENXBIO 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer COYA or MNPR?

In the previous week, Monopar Therapeutics had 5 more articles in the media than Coya Therapeutics. MarketBeat recorded 7 mentions for Monopar Therapeutics and 2 mentions for Coya Therapeutics. Coya Therapeutics' average media sentiment score of 0.72 beat Monopar Therapeutics' score of 0.50 indicating that Coya Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Coya Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Monopar Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Coya Therapeutics (COYA) Competitors

$5.86 +0.20 (+3.53%)

Closing price 04:00 PM Eastern

Extended Trading

$5.92 +0.06 (+1.01%)

As of 06:29 PM Eastern

Compare

COYA vs. RZLT, CABA, PRTA, RGNX, and MNPR

Should you buy Coya Therapeutics stock or one of its competitors? MarketBeat compares Coya Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Coya Therapeutics include Rezolute (RZLT), Cabaletta Bio (CABA), Prothena (PRTA), REGENXBIO (RGNX), and Monopar Therapeutics (MNPR). These companies are all part of the "pharmaceutical products" industry.

How does Coya Therapeutics compare to Rezolute?

Rezolute (NASDAQ:RZLT) and Coya Therapeutics (NASDAQ:COYA) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, valuation, dividends, media sentiment, risk, profitability and institutional ownership.

Rezolute has a beta of 0.54, indicating that its stock price is 46% less volatile than the broader market. Comparatively, Coya Therapeutics has a beta of 0.5, indicating that its stock price is 50% less volatile than the broader market.

Rezolute has a net margin of 0.00% compared to Coya Therapeutics' net margin of -266.10%. Coya Therapeutics' return on equity of -55.86% beat Rezolute's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rezolute	N/A	-58.82%	-54.48%
Coya Therapeutics	-266.10%	-55.86%	-48.86%

Rezolute currently has a consensus price target of $9.38, indicating a potential upside of 90.94%. Coya Therapeutics has a consensus price target of $15.33, indicating a potential upside of 161.66%. Given Coya Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Coya Therapeutics is more favorable than Rezolute.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rezolute	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.64
Coya Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

Coya Therapeutics has higher revenue and earnings than Rezolute. Rezolute is trading at a lower price-to-earnings ratio than Coya Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rezolute	N/A	N/A	-$74.41M	-$0.82	N/A
Coya Therapeutics	$7.95M	17.29	-$21.23M	-$1.15	N/A

83.0% of Rezolute shares are owned by institutional investors. Comparatively, 39.8% of Coya Therapeutics shares are owned by institutional investors. 14.8% of Rezolute shares are owned by company insiders. Comparatively, 6.1% of Coya Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, Rezolute had 2 more articles in the media than Coya Therapeutics. MarketBeat recorded 4 mentions for Rezolute and 2 mentions for Coya Therapeutics. Coya Therapeutics' average media sentiment score of 0.72 beat Rezolute's score of 0.31 indicating that Coya Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Rezolute	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Coya Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Coya Therapeutics beats Rezolute on 8 of the 15 factors compared between the two stocks.

How does Coya Therapeutics compare to Cabaletta Bio?

Cabaletta Bio (NASDAQ:CABA) and Coya Therapeutics (NASDAQ:COYA) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, institutional ownership, profitability, analyst recommendations, risk, valuation, dividends and media sentiment.

In the previous week, Cabaletta Bio and Cabaletta Bio both had 2 articles in the media. Cabaletta Bio's average media sentiment score of 0.95 beat Coya Therapeutics' score of 0.72 indicating that Cabaletta Bio is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cabaletta Bio	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Coya Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Coya Therapeutics has higher revenue and earnings than Cabaletta Bio. Coya Therapeutics is trading at a lower price-to-earnings ratio than Cabaletta Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cabaletta Bio	N/A	N/A	-$167.86M	-$1.96	N/A
Coya Therapeutics	$7.95M	17.29	-$21.23M	-$1.15	N/A

Cabaletta Bio presently has a consensus target price of $15.50, suggesting a potential upside of 385.89%. Coya Therapeutics has a consensus target price of $15.33, suggesting a potential upside of 161.66%. Given Cabaletta Bio's higher probable upside, equities research analysts clearly believe Cabaletta Bio is more favorable than Coya Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cabaletta Bio	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
Coya Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

Cabaletta Bio has a beta of 3.26, suggesting that its stock price is 226% more volatile than the broader market. Comparatively, Coya Therapeutics has a beta of 0.5, suggesting that its stock price is 50% less volatile than the broader market.

Cabaletta Bio has a net margin of 0.00% compared to Coya Therapeutics' net margin of -266.10%. Coya Therapeutics' return on equity of -55.86% beat Cabaletta Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cabaletta Bio	N/A	-131.58%	-96.46%
Coya Therapeutics	-266.10%	-55.86%	-48.86%

39.8% of Coya Therapeutics shares are held by institutional investors. 6.4% of Cabaletta Bio shares are held by insiders. Comparatively, 6.1% of Coya Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

Coya Therapeutics beats Cabaletta Bio on 8 of the 14 factors compared between the two stocks.

How does Coya Therapeutics compare to Prothena?

Coya Therapeutics (NASDAQ:COYA) and Prothena (NASDAQ:PRTA) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, earnings, dividends, institutional ownership, valuation, risk, media sentiment and profitability.

39.8% of Coya Therapeutics shares are owned by institutional investors. Comparatively, 97.1% of Prothena shares are owned by institutional investors. 6.1% of Coya Therapeutics shares are owned by company insiders. Comparatively, 10.4% of Prothena shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Coya Therapeutics has higher earnings, but lower revenue than Prothena. Coya Therapeutics is trading at a lower price-to-earnings ratio than Prothena, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Coya Therapeutics	$7.95M	17.29	-$21.23M	-$1.15	N/A
Prothena	$9.68M	52.40	-$244.09M	-$2.82	N/A

In the previous week, Coya Therapeutics had 1 more articles in the media than Prothena. MarketBeat recorded 2 mentions for Coya Therapeutics and 1 mentions for Prothena. Prothena's average media sentiment score of 1.25 beat Coya Therapeutics' score of 0.72 indicating that Prothena is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Coya Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Prothena	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Coya Therapeutics has a beta of 0.5, indicating that its share price is 50% less volatile than the broader market. Comparatively, Prothena has a beta of -0.31, indicating that its share price is 131% less volatile than the broader market.

Coya Therapeutics presently has a consensus price target of $15.33, suggesting a potential upside of 161.66%. Prothena has a consensus price target of $23.75, suggesting a potential upside of 145.10%. Given Coya Therapeutics' higher possible upside, equities analysts clearly believe Coya Therapeutics is more favorable than Prothena.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Coya Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
Prothena	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71

Prothena has a net margin of -260.92% compared to Coya Therapeutics' net margin of -266.10%. Prothena's return on equity of -43.44% beat Coya Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Coya Therapeutics	-266.10%	-55.86%	-48.86%
Prothena	-260.92%	-43.44%	-36.87%

Summary

Prothena beats Coya Therapeutics on 10 of the 16 factors compared between the two stocks.

How does Coya Therapeutics compare to REGENXBIO?

Coya Therapeutics (NASDAQ:COYA) and REGENXBIO (NASDAQ:RGNX) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, valuation, risk, institutional ownership, dividends, profitability, media sentiment and analyst recommendations.

Coya Therapeutics presently has a consensus price target of $15.33, suggesting a potential upside of 161.66%. REGENXBIO has a consensus price target of $23.82, suggesting a potential upside of 79.35%. Given Coya Therapeutics' higher possible upside, analysts plainly believe Coya Therapeutics is more favorable than REGENXBIO.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Coya Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
REGENXBIO	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75

39.8% of Coya Therapeutics shares are owned by institutional investors. Comparatively, 88.1% of REGENXBIO shares are owned by institutional investors. 6.1% of Coya Therapeutics shares are owned by company insiders. Comparatively, 14.2% of REGENXBIO shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Coya Therapeutics has a beta of 0.5, suggesting that its share price is 50% less volatile than the broader market. Comparatively, REGENXBIO has a beta of 1.04, suggesting that its share price is 4% more volatile than the broader market.

In the previous week, REGENXBIO had 4 more articles in the media than Coya Therapeutics. MarketBeat recorded 6 mentions for REGENXBIO and 2 mentions for Coya Therapeutics. Coya Therapeutics' average media sentiment score of 0.72 beat REGENXBIO's score of -0.18 indicating that Coya Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Coya Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
REGENXBIO	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Coya Therapeutics has higher earnings, but lower revenue than REGENXBIO. Coya Therapeutics is trading at a lower price-to-earnings ratio than REGENXBIO, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Coya Therapeutics	$7.95M	17.29	-$21.23M	-$1.15	N/A
REGENXBIO	$87.82M	7.82	-$193.88M	-$5.60	N/A

Coya Therapeutics has a net margin of -266.10% compared to REGENXBIO's net margin of -330.23%. Coya Therapeutics' return on equity of -55.86% beat REGENXBIO's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Coya Therapeutics	-266.10%	-55.86%	-48.86%
REGENXBIO	-330.23%	-232.50%	-61.02%

Summary

Coya Therapeutics and REGENXBIO tied by winning 8 of the 16 factors compared between the two stocks.

How does Coya Therapeutics compare to Monopar Therapeutics?

Coya Therapeutics (NASDAQ:COYA) and Monopar Therapeutics (NASDAQ:MNPR) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, risk, earnings, analyst recommendations, valuation, dividends, media sentiment and institutional ownership.

Monopar Therapeutics has a net margin of 0.00% compared to Coya Therapeutics' net margin of -266.10%. Monopar Therapeutics' return on equity of -12.84% beat Coya Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Coya Therapeutics	-266.10%	-55.86%	-48.86%
Monopar Therapeutics	N/A	-12.84%	-12.57%

Coya Therapeutics presently has a consensus target price of $15.33, indicating a potential upside of 161.66%. Monopar Therapeutics has a consensus target price of $108.75, indicating a potential upside of 11.21%. Given Coya Therapeutics' higher possible upside, equities analysts clearly believe Coya Therapeutics is more favorable than Monopar Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Coya Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
Monopar Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	3.00

In the previous week, Monopar Therapeutics had 5 more articles in the media than Coya Therapeutics. MarketBeat recorded 7 mentions for Monopar Therapeutics and 2 mentions for Coya Therapeutics. Coya Therapeutics' average media sentiment score of 0.72 beat Monopar Therapeutics' score of 0.50 indicating that Coya Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Coya Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Monopar Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

39.8% of Coya Therapeutics shares are held by institutional investors. Comparatively, 1.8% of Monopar Therapeutics shares are held by institutional investors. 6.1% of Coya Therapeutics shares are held by company insiders. Comparatively, 9.7% of Monopar Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Coya Therapeutics has a beta of 0.5, meaning that its stock price is 50% less volatile than the broader market. Comparatively, Monopar Therapeutics has a beta of 1.46, meaning that its stock price is 46% more volatile than the broader market.

Monopar Therapeutics has lower revenue, but higher earnings than Coya Therapeutics. Monopar Therapeutics is trading at a lower price-to-earnings ratio than Coya Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Coya Therapeutics	$7.95M	17.29	-$21.23M	-$1.15	N/A
Monopar Therapeutics	N/A	N/A	-$13.72M	-$1.90	N/A

Summary

Monopar Therapeutics beats Coya Therapeutics on 10 of the 16 factors compared between the two stocks.

Get Coya Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding COYA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

COYA vs. The Competition

Export

Metric	Coya Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$137.48M	$3.76B	$6.95B	$12.40B
Dividend Yield	N/A	2.21%	2.67%	6.14%
P/E Ratio	-5.10	21.80	27.73	24.94
Price / Sales	17.29	330.45	535.76	98.37
Price / Cash	N/A	141.54	47.99	59.26
Price / Book	2.84	8.66	10.91	6.46
Net Income	-$21.23M	$23.81M	$3.57B	$336.81M
7 Day Performance	14.23%	5.64%	3.65%	2.55%
1 Month Performance	23.89%	8.26%	4.46%	0.33%
1 Year Performance	1.38%	64.77%	35.83%	25.76%

Coya Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
COYA Coya Therapeutics	2.3303 of 5 stars	$5.86 +3.5%	$15.33 +161.7%	-0.7%	$137.48M	$7.95M	N/A	6
RZLT Rezolute	3.0933 of 5 stars	$4.89 -5.0%	$9.38 +91.7%	+12.0%	$495.90M	N/A	N/A	40	Analyst Downgrade Gap Down
CABA Cabaletta Bio	2.6305 of 5 stars	$3.02 +0.3%	$15.50 +413.2%	+91.7%	$490.80M	N/A	N/A	50	Gap Down
PRTA Prothena	3.0705 of 5 stars	$9.55 +4.4%	$23.75 +148.7%	+53.0%	$479.03M	$9.68M	N/A	130	Positive News
RGNX REGENXBIO	3.2718 of 5 stars	$9.95 +9.7%	$23.82 +139.4%	+59.1%	$468.90M	$170.44M	N/A	370	Analyst Forecast Insider Trade Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:COYA) was last updated on 7/2/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Coya Therapeutics (COYA) Competitors

COYA vs. RZLT, CABA, PRTA, RGNX, and MNPR

How does Coya Therapeutics compare to Rezolute?

Summary

How does Coya Therapeutics compare to Cabaletta Bio?

Summary

How does Coya Therapeutics compare to Prothena?

Summary

How does Coya Therapeutics compare to REGENXBIO?

Summary

How does Coya Therapeutics compare to Monopar Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

COYA vs. The Competition

Coya Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Coya Therapeutics (COYA) Competitors

COYA vs. RZLT, CABA, PRTA, RGNX, and MNPR

How does Coya Therapeutics compare to Rezolute?

Which has more risk and volatility, RZLT or COYA?

Is RZLT or COYA more profitable?

Do analysts prefer RZLT or COYA?

Which has higher valuation & earnings, RZLT or COYA?

Do institutionals & insiders hold more shares of RZLT or COYA?

Does the media prefer RZLT or COYA?

Summary

How does Coya Therapeutics compare to Cabaletta Bio?

Does the media prefer CABA or COYA?

Which has higher earnings & valuation, CABA or COYA?

Do analysts recommend CABA or COYA?

Which has more volatility & risk, CABA or COYA?

Is CABA or COYA more profitable?

Do insiders & institutionals hold more shares of CABA or COYA?

Summary

How does Coya Therapeutics compare to Prothena?

Do insiders and institutionals have more ownership in COYA or PRTA?

Which has better valuation & earnings, COYA or PRTA?

Does the media favor COYA or PRTA?

Which has more volatility and risk, COYA or PRTA?

Do analysts recommend COYA or PRTA?

Is COYA or PRTA more profitable?

Summary

How does Coya Therapeutics compare to REGENXBIO?

Do analysts recommend COYA or RGNX?

Do insiders & institutionals have more ownership in COYA or RGNX?

Which has more volatility & risk, COYA or RGNX?

Does the media prefer COYA or RGNX?

Which has better valuation & earnings, COYA or RGNX?

Is COYA or RGNX more profitable?

Summary

How does Coya Therapeutics compare to Monopar Therapeutics?

Is COYA or MNPR more profitable?

Do analysts recommend COYA or MNPR?

Does the media prefer COYA or MNPR?

Do institutionals & insiders hold more shares of COYA or MNPR?

Which has more volatility and risk, COYA or MNPR?

Which has higher valuation & earnings, COYA or MNPR?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

COYA vs. The Competition

Coya Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools